Merck and Ridgeback Present Results of Molnupiravir in P-III MOVe-OUT Trial for the Treatment of COVID-19 at ASTMH 2021
Shots:
- The P-III MOVe-OUT trial evaluates molnupiravir vs PBO in non-hospitalized adult patients with COVID-19 with 1 risk factor associated with poor disease outcomes & symptom onset within 5 days before randomization
- At the interim analysis, the therapy showed a ~50% reduction in risk of hospitalization or death; patients were hospitalized or died (7.3% vs 14.1%) @ 29Day following randomization & no deaths were reported
- The companies continue to discuss additional measures and collaborations to accelerate global access to molnupiravir. The therapy is also being evaluated in the P-III MOVe-AHEAD study as monothx. for post-exposure prophylaxis to prevent COVID-19 within households
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com